Sonic Healthcare (ASX:SHL) has announced its financial results for the half-year ended Dec. 31, 2024, reporting a net profit of $237 million on revenues of approximately $4.7 billion.
This reflects a 17% increase in net profit and an 8.4% rise in revenue compared to the previous year.
The company recorded an EBITDA of $827 million, up 12.3%, with strong organic revenue growth of 6.1% contributing to a margin expansion of 60 basis points.
Sonic Healthcare's efforts to control costs were evident as labour costs as a percentage of revenue reduced by 50 basis points.
"Our operations have performed to our expectations in the half-year, with our management teams around the world acutely focused on achieving organic growth and margin improvement, in a setting of tight cost control," said Dr. Colin Goldschmidt, CEO of Sonic Healthcare.
Dr. Goldschmidt also highlighted that Sonic Healthcare's acquisitions, such as Synlab Suisse and the Dr. Risch Group, are on track to deliver future synergies.
The acquisition of LADR Laboratory Group will be completed on July 1 and is expected to be immediately earnings per share accretive.
Sonic Healthcare announced a progressive dividend policy, increasing the interim dividend by 1 cent to 44 cents per share.
The company remains committed to delivering ongoing earnings growth, driven by organic revenue growth and enhanced operational leverage.